Integer Holdings Valuation
Is WGB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of WGB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: WGB (€126) is trading above our estimate of fair value (€66.87)
Significantly Below Fair Value: WGB is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for WGB?
Key metric: As WGB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is WGB's PE Ratio? | |
|---|---|
| PE Ratio | 38.4x |
| Earnings | US$116.40m |
| Market Cap | US$4.47b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.3x |
| Enterprise Value/EBITDA | 17x |
| PEG Ratio | 1.8x |
Price to Earnings Ratio vs Peers
How does WGB's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.8x | ||
AFX Carl Zeiss Meditec | 25.7x | 16.3% | €5.2b |
EUZ Eckert & Ziegler | 21.3x | 4.6% | €802.1m |
DRW3 Drägerwerk KGaA | 7.2x | 2.0% | €792.8m |
SHL Siemens Healthineers | 28.8x | 14.2% | €56.0b |
WGB Integer Holdings | 38.4x | 20.8% | €4.5b |
Price-To-Earnings vs Peers: WGB is expensive based on its Price-To-Earnings Ratio (38.4x) compared to the peer average (20.8x).
Price to Earnings Ratio vs Industry
How does WGB's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: WGB is expensive based on its Price-To-Earnings Ratio (38.4x) compared to the European Medical Equipment industry average (29.7x).
Price to Earnings Ratio vs Fair Ratio
What is WGB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 38.4x |
| Fair PE Ratio | 27.5x |
Price-To-Earnings vs Fair Ratio: WGB is expensive based on its Price-To-Earnings Ratio (38.4x) compared to the estimated Fair Price-To-Earnings Ratio (27.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €126.00 | €130.51 +3.6% | 3.9% | €136.18 | €120.43 | n/a | 8 |
| Nov ’25 | €115.00 | €130.51 +13.5% | 3.9% | €136.18 | €120.43 | n/a | 8 |
| Oct ’25 | €115.00 | €122.64 +6.6% | 5.0% | €130.99 | €112.93 | n/a | 8 |
| Sep ’25 | €117.00 | €117.73 +0.6% | 7.6% | €126.10 | €96.16 | n/a | 9 |
| Aug ’25 | €107.00 | €119.64 +11.8% | 7.6% | €128.14 | €97.72 | n/a | 9 |
| Jul ’25 | €106.00 | €118.98 +12.2% | 8.6% | €128.45 | €95.18 | n/a | 8 |
| Jun ’25 | €111.00 | €118.98 +7.2% | 8.6% | €128.45 | €95.18 | n/a | 8 |
| May ’25 | €104.00 | €118.12 +13.6% | 9.3% | €129.58 | €96.02 | n/a | 7 |
| Apr ’25 | €107.00 | €107.27 +0.2% | 11.9% | €127.00 | €92.70 | n/a | 7 |
| Mar ’25 | €102.00 | €100.23 -1.7% | 7.7% | €114.16 | €92.81 | n/a | 6 |
| Feb ’25 | €95.00 | €93.15 -2.0% | 4.1% | €96.61 | €86.58 | n/a | 5 |
| Jan ’25 | €89.00 | €89.56 +0.6% | 8.3% | €98.47 | €79.89 | n/a | 5 |
| Dec ’24 | €78.50 | €89.91 +14.5% | 9.1% | €100.32 | €81.39 | n/a | 5 |
| Nov ’24 | €77.50 | €89.91 +16.0% | 9.1% | €100.32 | €81.39 | €115.00 | 5 |
| Oct ’24 | €74.50 | €91.74 +23.1% | 6.9% | €98.62 | €81.88 | €115.00 | 5 |
| Sep ’24 | €79.00 | €90.41 +14.4% | 6.7% | €96.15 | €79.82 | €117.00 | 6 |
| Aug ’24 | €84.00 | €90.41 +7.6% | 6.7% | €96.15 | €79.82 | €107.00 | 6 |
| Jul ’24 | €81.00 | €83.90 +3.6% | 3.9% | €89.49 | €80.17 | €106.00 | 6 |
| Jun ’24 | €76.50 | €83.90 +9.7% | 3.9% | €89.49 | €80.17 | €111.00 | 6 |
| May ’24 | €74.00 | €83.17 +12.4% | 4.1% | €87.50 | €78.39 | €104.00 | 4 |
| Apr ’24 | €71.00 | €79.54 +12.0% | 2.2% | €82.52 | €77.94 | €107.00 | 4 |
| Mar ’24 | €71.00 | €82.47 +16.2% | 2.5% | €85.31 | €80.57 | €102.00 | 3 |
| Feb ’24 | €62.00 | €82.42 +32.9% | 3.4% | €85.27 | €79.58 | €95.00 | 2 |
| Jan ’24 | €63.50 | €82.42 +29.8% | 3.4% | €85.27 | €79.58 | €89.00 | 2 |
| Dec ’23 | €70.00 | €93.33 +33.3% | 9.5% | €105.38 | €84.30 | €78.50 | 3 |
| Nov ’23 | €62.00 | €93.33 +50.5% | 9.5% | €105.38 | €84.30 | €77.50 | 3 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Fagron
€1.4b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
4A5
€18.54
7D
-1.2%
1Y
9.3%
Shandong Weigao Group Medical Polymer
HK$20.4b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.53
7D
-9.5%
1Y
-41.3%
CVS Health
US$66.9b
Provides health solutions in the United States.
CVS
US$50.67
7D
-2.6%
1Y
-18.8%